VAT Group Posts Preliminary Q4 Sales Ahead Of Prior Guidance Range

VAT Group reported preliminary Q4 sales of CHF 257 million, beating its guidance range of CHF 225–245 million while showing a 9% year‑on‑year decline (effectively down 1% after adjusting for sales shifted from Q3). Preliminary Q4 orders were around CHF 305 million, up 14% year‑on‑year, and the company said full-year 2025 results and an updated 2026 outlook will be released on March 3, 2026 — a beat on guidance and stronger order intake that could support the share price ahead of the formal results.

Analysis

Market structure: VAT’s preliminary Q4 beat (CHF257m vs guidance CHF225–245m) with orders CHF305m (+14% YoY) signals near-term demand resilience in vacuum-components for semiconductor and display capex. Direct winners: VAT (VACN.SW) and upstream semiconductor equipment suppliers (ASML, LRCX, AMAT) via higher bookings and potential pricing leverage; losers include lower-tier component suppliers with limited backlog or high customer concentration. The sales timing shift (Q3→Q4) highlights lumpiness but orders>sales implies backlog growth that should support Q1–Q2 revenue visibility.

Risk assessment: Tail risks include a semiconductor capital-spend pullback (20–30% cut scenario), sudden order cancellations, CHF strength compressing exported margins, and single-customer concentration risk; any of these could remove 10–30% of expected EBITDA. Immediate (days) risk is headline-driven volatility; short-term (weeks to March 3) hinge on the full-year 2026 outlook; long-term depends on multi-quarter capex cycles. Hidden dependency: revenue recognition/timing shifts mask underlying demand—watch backlog conversion and gross margin trends.

Trade implications: Tactical: establish a small core long in VACN.SW (2–3% portfolio) into the March 3 release because orders momentum offers asymmetric upside, hedged with a 3‑month 10% OTM protective put or a tight call-debit spread to limit downside. Relative-value: pair long VACN.SW vs short MKSI (MKS Instruments) at 0.6x notional to neutralize semi-cycle beta and capture valve-specific recovery over 1–3 months. Rotate 1–2% weight into ASML and LRCX for broader equipment exposure if VAT’s March outlook is positive.

Contrarian angles: Consensus may treat the YoY sales decline as weakness, but adjusted sales down ~1% (after timing) plus +14% orders suggests troughing, not structural decline—this is often underpriced. The market could overreact if VAT’s March outlook is conservative; conversely, a strong backlog conversion could force customers to renegotiate prices or cancel excess orders if capex slows. Key catalysts: March 3 full-year 2025 results, OEM capex updates, and major customer earnings in the next 30–60 days.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in VACN.SW (VAT Group) within 5–15 trading days ahead of the March 3, 2026 results; target a 15–25% upside on confirmed 2026 guidance upgrades, set a hard stop-loss at -10% or hedge with a 3‑month 10% OTM put (buy-to-protect).
• If prefer options, deploy a low-cost directional: buy an end-of-March 2026 ATM call and sell a 20% OTM call (debit call spread) sized at 25% of the intended equity exposure to capture post-release re-rating while capping premium outlay.
• Initiate a relative-value pair trade: long VACN.SW vs short MKSI (MKS Instruments) at ~0.6x notional to hedge macro cyclical risk; hold 1–3 months and unwind if VAT orders fall below CHF250m or MKSI outperforms by >10%.
• Rotate 1–2% portfolio weight into semiconductor equipment leaders (ASML, LRCX) and reduce generic industrial cyclicals by same amount if March 3 guidance confirms backlog conversion; cut these rotations if 2026 revenue guidance is revised down >5% YoY or VAT reports material order cancellations.